The typical clinical presentation of dopa-responsive dystonia, which is also called Segawa disease, is a young age of onset, with predominance in females, diurnal fluctuation of lower limb dystonia, and fair response to low-dose levodopa. This disease has both autosomal dominant and autosomal recessive inheritance. Autosomal dominant Segawa disease is caused by GCH1 mutation on chromosome 14q22.1-q22.2. Here, we report the case of a male patient with genetically confirmed Segawa disease and atypical presentations including no diurnal symptom fluctuation and insufficient response to levodopa. The patient's father who had the same mutation presented parkinsonism in old age. We also review the literature to address the broad clinical heterogeneity of Segawa disease and the influence of onset age on clinical presentation.
| INTRODUCTION
Segawa disease, also called dopa-responsive dystonia (DRD), is an autosomal inherited disease classified as a dystonia-plus syndrome; it was first described by Segawa, Ohmi, Itoh, Aoyama, and Hayakawa (1971) as a disease with marked diurnal fluctuation of dystonia. Segawa disease is characterized by a typical clinical presentation of youngonset lower limb dystonia (Van Hove et al., 2006) and the dystonia becomes more severe near the end of the day (Nygaard, Marsden, & Duvoisin, 1988) . Another characteristic is that the dystonia favorably responds to low-dose levodopa (Nygaard et al., 1988) . The prevalence of this disease is approximately 0.5-1 per million (Segawa, Nomura, & Nishiyama, 2003; Tg, 1993; Zirn et al., 2008) and the data could be highly under-representative due to mild symptoms in some patients; because of a higher penetrance of the causative genes among females, the incidence of Segawa disease is 2-4 higher in females than in males (Furukawa et al., 1998; Steinberger et al., 1998) . With time, the lower limb dystonia progresses to generalized dystonia (Segawa et al., 2003) .
Segawa disease is caused by to a mutation in the guanosine triphosphate cyclohydrolase 1 gene (GCH1) on chromosome 14q22.1-q22.2 (Ichinose et al., 1994; Segawa et al., 2003) .
GCH1 is the rate-limiting enzyme in tetrahydrobiopterin (BH4) synthesis, and BH4 is a cofactor for tyrosine hydroxylase (Ichinose et al., 1994) . Patients with GCH1 mutations demonstrated reduced GCH1 activity, thus leading to decreased dopamine levels and resulting in dystonia (Nagatsu, Levitt, & Udenfriend, 1964) . However, atypical presentations of Segawa disease, such as that with incomplete response to levodopa (Bandmann et al., 1996; Regula, Thoden, & Meinck, 2007; Romstad et al., 2003) and presentation as cerebral palsy, spastic paraplegia, pure parkinsonism, or proximal weakness and hypotonia (Bandmann, Marsden, & Wood, 1998; Bandmann et al., 1996; Fink et al., 1988; Kong, Ko, Tong, & Lam, 2001; Nygaard et al., 1988) , have been reported in a relatively few cases. Here, we report a rare case of Segawa disease with an atypical presentation and provide a literature review addressing the clinical heterogeneity of Segawa disease.
| CASE REPORT
A 43-year-old man, without underlying diseases, had left-foot There was no copy number variation in these genes. Genetic testing for dystonia-causing genes such as Tor1A, TH, or PRKRA was not 
Image of 99mTc-TRODAT-1 SPECT of index patient. The image revealed bilateral symmetry of the normally shaped caudate nucleus and putamen. Symmetrical distribution of dopaminergic radioactivity was noted in the striatum. The result revealed no presynaptic uptake decreasing conducted as the subject's presentation was not consistent with the phenotype reported for each of these mutations. Because of the parkinsonian presentation observed in his father and possibility of inheritance, we arranged a genetic study for his father; he was also confirmed to have the same gene mutation at exon 6 c.670 A>G.
The patient's grandmother had already passed away; therefore, no further genetic study could be performed. We further conducted genetic study of c.670 in a cohort of 173 normal controls with 346 chromosomes, and no c.670 A>G was found. Moreover, because the patient did not have fair response to levodopa, we performed botulinum injection over his anterior tibialis, tibialis posterior, and extensor hallucis longus muscles. Consequently, his dystonia improved considerably from Global Dystonia Rating Scale (GDS) 5 to 1. The patient was satisfied with the treatment results.
| DISCUSSION
We report the case of an atypical presentation of Segawa disease including insufficient drug response and no diurnal fluctuation of dystonia. A good response to low-dose levodopa is considered characteristic for the diagnosis of Segawa disease (Müller, Steinberger, & Topka, 2002; Nygaard et al., 1988) . Diurnal fluctuation is often present in the affected patients (Nygaard et al., 1988) and the rate of this fluctuation is approximately 94% (Liu et al., 2010) . After searching PubMed for reports on Segawa disease, we found only a few reports mentioning poor or incomplete levodopa response (Bandmann et al., 1996; Grimes, Barclay, Duff, Furukawa, & Lang, 2002; Regula et al., 2007; Romstad et al., 2003; Tadic et al., 2012; Tassin et al., 2000) .
One patient had tyrosine hydroxylase deficiency and other cases had GCH1 mutation. According to the previous reports, a daily levodopa dose of <20 mg/kg is sufficient for treating Segawa disease without a DTI (Segawa et al., 2003) whereas with a DTI, a daily dose of 300 mg, and sometimes 400 mg, is required (Nygaard, Snow, & Fahn, 1993; Steinberger et al., 2000) . (Segawa et al., 2003) . In the adult-onset group of Trender-Gerhard's study, all the adult patients presented tremors or parkinsonism as main symptoms. In our case, the patient's father was confirmed to have GCH1 mutation with typical parkinsonian features, which is also similar to the report in the previous study (Segawa et al., 2003; Trender-Gerhard et al., 2009) . A similar classification has been summarized previously (Bernal-Pacheco et al., 2013) . According to the literature and our observations, we conclude that mild symptoms of Segawa disease tend to occur in young-onset male patients and that pure parkinsonism could be a common feature in adult-onset male patients with CGH1 mutation.
For the completely different clinical presentation of Segawa disease in our report, we further searched Pubmed with the keywords "Parkinsonism" and "Segawa" or "DRD, " and we found a few familial study articles on Segawa disease with symptoms of both dystonia and parkinsonism that are similar to those in our familial study (Table 1) . In these families, adult-onset cases apparently tended to present pure parkinsonism F I G U R E 3 Genetic study of the patient. A mutation was noted at exon 6 c.670 A>G (Table 2 ); in addition, the number of adult-onset male patients was higher than that of female patients (Table 2) . Young-onset patients could have more varied presentation but still predominantly had pure dystonia or parkinsonism with dystonia (Table 3 ). In the meta-analysis study of Tadic et al., adult-onset patients could have more parkinsonian presentation than young-onset patients and this result is also not against our finding (Tadic et al., 2012) . In a recent study of Mencacci et al. (2014) they found GCH1 gene could possibly have a correlation with Parkinson's disease via whole exome sequencing;. Another study of GCH1 single-nucleotide polymorphisms revealed possible increased risk of Parkinson's disease (Chen et al., 2016) . Whether GCH1 mutation could be pathogenic to Parkinson's disease remained uncertain, but these results could possibly give us a new idea that parkinsonism may not necessary just be symptoms of DRD.
Until 2016, 229 mutations were collected in the Human Gene Mutation Database (http://www.hgmd.org/). The GCH1 mutation at exon 6 c.670 noted in our patient has been reported previously in patients with DRD (Bandmann et al., 1996; Jarman, Bandmann, Marsden, & Wood, 1997; Mencacci et al., 2014) . Although this is not the first report regarding this mutation location, the previous reports reported either lysine to arginine or lysine to threonine change and cause conservative amino acid change or stop codon, whereas we discovered a lysine to glucine change in our case (Bandmann et al., 1996; Jarman et al., 1997) . We also confirmed that lysine to glucine change is not a variant but a mutation in our study. The clinical presentations of each patient are different, and the mechanisms of this mutation to cause various clinical features are still not well understood.
We reviewed a previous report and found that Arg249Ser, Ser81Pro, Ser76X, Gly203Arg, 249del A, and IVS5+3insT have been reported in Taiwan (Hwu, Chiou, Lai, & Lee, 2000; Wu-Chou et al., 2010) . In a group of Chinese Han patients, the locus included Gly155Ser in exon 3 (Hu et al., 2011) ; Met137Arg in exon 2 (Hu et al., 2011) ; Gly203Arg in exon 5 (Hu et al., 2011; Liu et al., 2010; Yu, Zhou, Hu, & Xu, 2013) ; Cases within each family had either pure parkinsonism or dystonia with or without parkinsonism. Patients with uncertain sign or onset age were excluded.
Gln161Pro (Xie et al., 2006) ; Lys224Arg (Xie et al., 2006) ; Met1Thr (Cao et al., 2010) ; Ser80Asn (Cao et al., 2010) ; Leu82Pro (Cao et al., 2010) ; and IVS5+3 del AAGT (Cao et al., 2010) ; Met102Lys (Liu et al., 2010) ; Thr186Ile (Liu et al., 2010) ; Tyr75Cys (Cai et al., 2013) ;
Ala98Val (Cai et al., 2013) ; Ile135Thr (Cai et al., 2013) ; Leu91Val (Wu et al., 2008) ; Pro95Leu (Wu et al., 2008) ; Val204Gly (Wu et al., 2008) and 628delC (Wu et al., 2008) ; Met1Ile (Li et al., 2007) ; Thre94Met (Yu et al., 2013) ; Leu145Phe (Yu et al., 2013) ; and c. 453+6G>T (Yu et al., 2013) . A study of 40 patients with Segawa disease suggested that most mutations in Chinese patients with Segawa disease are clustered in two regions-the 210-360 and 550-650 base pair (Yu et al., 2013 ).
In conclusion, we report a case with an atypical presentation of Segawa disease and aim to address the broad clinical heterogeneity of Segawa disease.
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